BDBM312391 3-[3-(3-Trifluoromethyl-[1,2,4]oxadiazol-5-yl)-5,6-dihydro-4H-cyclopenta[b]thiophen-2-ylcarbamoyl]-bicyclo[2.2.2]oct-2-ene-2-carboxylic acid::US9604977, Example 137

SMILES: OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCc2c1-c1nc(no1)C(F)(F)F

InChI Key: InChIKey=AVEIGYVJUOVLNL-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 312391   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Fatty acid-binding protein 5 (FABP5) (Homo sapiens (Human))	BDBM312391 (3-[3-(3-Trifluoromethyl-[1,2,4]oxadiazol-5-yl)-5,6...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCc2c1-c1nc(no1)C(F)(F)F |t:3,(1.21,-4.68,;2.75,-4.68,;3.52,-6.02,;3.52,-3.35,;2.75,-2.02,;3.52,-.68,;5.06,-.68,;5.83,-2.02,;5.06,-3.35,;3.73,-2.58,;4.86,-1.45,;1.21,-2.02,;.44,-3.35,;.44,-.68,;-1.1,-.68,;-2,-1.93,;-3.47,-1.45,;-4.93,-1.93,;-5.83,-.68,;-4.93,.56,;-3.47,.09,;-2,.56,;-1.23,1.9,;.23,2.37,;.23,3.91,;-1.23,4.39,;-2.14,3.14,;1.57,4.68,;2.9,3.91,;.8,6.02,;2.34,6.02,)| Show InChI InChI=1S/C20H18F3N3O4S/c21-20(22,23)19-25-16(30-26-19)14-10-2-1-3-11(10)31-17(14)24-15(27)12-8-4-6-9(7-5-8)13(12)18(28)29/h8-9H,1-7H2,(H,24,27)(H,28,29)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	70	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair
Fatty acid-binding protein 4 (FABP4) (Homo sapiens (Human))	BDBM312391 (3-[3-(3-Trifluoromethyl-[1,2,4]oxadiazol-5-yl)-5,6...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCc2c1-c1nc(no1)C(F)(F)F |t:3,(1.21,-4.68,;2.75,-4.68,;3.52,-6.02,;3.52,-3.35,;2.75,-2.02,;3.52,-.68,;5.06,-.68,;5.83,-2.02,;5.06,-3.35,;3.73,-2.58,;4.86,-1.45,;1.21,-2.02,;.44,-3.35,;.44,-.68,;-1.1,-.68,;-2,-1.93,;-3.47,-1.45,;-4.93,-1.93,;-5.83,-.68,;-4.93,.56,;-3.47,.09,;-2,.56,;-1.23,1.9,;.23,2.37,;.23,3.91,;-1.23,4.39,;-2.14,3.14,;1.57,4.68,;2.9,3.91,;.8,6.02,;2.34,6.02,)| Show InChI InChI=1S/C20H18F3N3O4S/c21-20(22,23)19-25-16(30-26-19)14-10-2-1-3-11(10)31-17(14)24-15(27)12-8-4-6-9(7-5-8)13(12)18(28)29/h8-9H,1-7H2,(H,24,27)(H,28,29)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	20	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair